The glucagon-like peptide-1 (GLP-1) receptor agonists is a potential medication as insulin-assisted for T1D, with various effects, such as promoting glucose-stimulated insulin secretion and reducing glucagon secretion (58, 59). This evidence concerns the gene INS and type 1 diabetes mellitus.